Abstract | To improve future drug development and patient management for patients with castration-resistant prostate cancer (CRPC), surrogate biomarkers that are linked to relevant outcomes are urgently needed. A biomarker must be measurable, reproducible, linked to relevant clinical outcomes, and demonstrate clinical utility. This area is rapidly evolving, with recent trials in patients with CRPC incorporating the detection of circulating tumour cells (CTCs), imaging, and patient-reported outcome biomarkers. We discuss the framework for the development of biomarkers for CRPC, including different categories and contexts of use. We also highlight the requirements of analytical validation, the sequence of trials needed for clinical validation and regulatory approval, and the future outlook for imaging and CTC biomarkers.
Introduction
To establish a new treatment standard of care requires demonstration of a clinical benefit or that the treatment alters an outcome measure known to be a substitut e or surrogate for that benefit. The success of recent phase III trials for castration-resistant prostate cancer (CRPC) has led to the approval of several agents with diverse mechanisms of action [1] [2] [3] [4] [5] [6] and new treatment standards. However, there were also notable failures, [7] [8] [9] [10] [11] which highlight the challenges in developing new therapies and improving outcomes for patients with CRPC. For example, treatment with sipuleuce l-T showed an overall survival benefit, despite a modest effect on prostate-specific antigen (PSA) levels and no effect on disease progression. 1 This example illustrates that clinical outcome was not correlated with the studied biomarker. Furthermore, a placebo-controlled trial demonstrated a survival benefit for radium-223 chloride and a delay in time to PSA progression, 12 although there was no significant difference in PSA response rate (>50% decline from baseline) in the study-drug arm relative to placebo. 13 Finally, androgen receptor (AR) signalling in hibitors can lower PSA levels without prolonging survival. 14 Bone is the most-common site of metastatic spread in patients with CRPC. Assessment of bone metastas es remains problematic because of the lack of standards for using and interpreting imaging modalities to detect and monitor disease in bone. The need for new biomarkers becomes all the more crucial as additional life-prolongi ng treatment options emerge, making overall survival trial results difficult to interpret because downstream therapies after trial participation might alter the survival equatio n. 15 This crowded therapeutic landscape increases the difficulty of demonstrating a survival benefit for the next promising approach.
All of these factors highlight the need for clinically re levant intermediate end points that are surrogates for overall survival, and that can reliably inform phase III outcomes and/or lead to drug approvals in their own right. Validated intermediate end point biomarkers would shorten the time to complete a clinical trial and enable a greater number of therapies to be tested within a given time frame. Predictive biomarkers are also needed to enable trials to enroll and treat patients most likely to respond to a particular treatment based on the patient's disease character istics. Although the need to explore new biomarkers is apparent, there is too little appreciation and understanding of the rigorous structure that is required to develop a new biomarker for a specific context of use. We provide a detailed framework for biomarker testing in CRPC that is focused on determining prognosis and assessing treatment effects. In 2008, the Prostate Cancer Working Group (PCWG2) presented a new framework for clinical trial conduct in CRPC 16 in response to a challenge by the FDA. The new paradigm more-directly aligned trial objectives with clinical practice and patient benefit by reframing early post-treatment response outcomes as the control, relief or elimination of disease manifestations present when treatment is initiated, and reframing timeto-event outcomes indicative of progression as preventing or delaying disease ma nifestations, including death from disease, from occurring in the future. The indications for drug approvals in CRPC are consistent with this paradigm (Table 1) . PCWG2 stated that trials should be designed for patients in discrete clinical states that represent key milestones and decision points in the disease continuum, which, for CRPC, are focused primarily on prior chemotherapy exposure. This Review builds upon the PCWG2 framework and terminology by considering trial eligibility (the decision to treat a patient) and outcomes (end points) by their usefulness (utility). We focus on the analytical validity of the sp ecific biomarker measurement, and the level of evidence needed to clinically validate its use in a sp ecific context to inform a medical decision.
Overview of biomarker development
Biomarkers are characteristics that can be objectively measured and evaluated as indicators of normal processes, pathogenic processes, or pharmacological responses to a therapeutic intervention. 17 Biomarkers can be clinical parameters (such as age, performance status), laboratory measures (such as PSA), imaging-based measures, or genetic and molecular determinants. Biomarker development consists of two separate components: an alytical validation and clinical validation. 18, 19 For analytical validation of a biomarker, data are ge nerated to describe the performance characteristi cs of the biomarker measurement itself; these include the device, Key points ■ Improving current treatment for patients with castration-resistant prostate cancer requires new biomarkers and surrogate end points for clinical trials ■ Of highest priority are biomarkers that reflect clinical benefit, and predictive biomarkers to guide the selection of treatment most likely to work in the individual patient ■ The development and approval processes for biomarkers are rigorous and lengthy, requiring analytically valid assays and a sequence of trials that support the use of a biomarker in a specific context ■ The investment of resources and time will be recovered by achieving streamlined clinical trials and better selection of new therapies for development ■ Promising emerging biomarkers for castration-resistant prostate cancer include circulating tumour cells and new methods for imaging bone metastases imaging modality, or assay, and the range of co nditions under which the measurement gives reproducib le and accurate results. Analytical validation includes the preanaly tical assessment of specimen and/or image ac quisition, processing and storage; determining the consistency and reproducibility of the analysis each time it is performed at the same or independent laboratories, and quality control measures; and the post-analytical data reduction, including how the results will be recorded, reported, and the specific measures that will be associated with clinical outcome. An example of a measure of consistency is the concordance correlation coefficient, which determines the variation of replicate pairs plotted around a 45° line through the origin (Figure 1 ). 20 After analytic al validity has been established, clinical studies are initiated to establish clinical validity: the demonstration that the biomarker is fit for purpose for the specific context of use-that is, that the results will inform the medical decision. 21 Establishing clinical validity requires trials designed to address the biomarker question.
Clinical utility demonstrates how much additional informatio n the biomarker provides relative to what is cu rrently available; 22 both cost and clinical utility affect reimbursement. Although the FDA does not formally request clinical utility in the biomarker development process, it is a vital consideration that will impact on how widely the marker is used and ultimately reimbursed by private and public payers. For example, clinical utility would be a decidin g factor when comparing the value of a costly molecular analysis of a tumour compared to inexpensive clinical parameters ro utinely available in practice to assess prognosis.
Clinical qualification is an additional step in bi omarker development that has regulatory implications. A clinically qualified biomarker is one for which sufficient ev idence has been generated for FDA acceptance for use in regulatory submissions, without a re-review of the data supportin g the use of the biomarker. A biomarker that qualifies for a clinical benefit end point (an improvement in survival time or patient function) could potentially lead to accelerated drug approval. 23 The level of evidence needed for clinical qualification involves prospective testing of the biomarker in multiple phase III trials. 24 The FDA has four specific categories for contexts of biomarker use: prognostic, predictive, responseindicat or, and efficacy-response (Table 2) . Considered in the PCWG2 framework, 16 prognostic and predictive biomarkers include pretreatment characteristics of the patient and the tumour. Such biomarkers can be identified retrospectively after a trial has been completed and can form part of the eligibility criteria for a future trial. Response-indicator and efficacy-response biomarkers are those occurring after treatment and represent an effect of the treatment. Alternatively, biomarker use can be classified by the PCWG2 recommendation s as pr etreatment or post-treatment (Table 3) .
A recent change in the regulatory requirements for cl inical trials evaluating predictive biomarkers of sensitivity to a drug is noteworthy. 25 Under the revised guidanc e, if the results of a pretreatment biomarker assay are used to guide the choice of one treatment versus another in a clinica l trial, the assay, and the device used to measure it, are subject to regulatory review for an Investigational Device Exemption (IDE) and must be formally approved for investigational use by the FDA. Once clinical development starts, the assay itself cannot be changed. A bi omarker that informs the choice of a specific therapy on an investigational protocol is called an integral biomarker and, if it is shown to be predictive, may require a companio n diagnostic assay that meets regulatory requirements before the drug itself can be approved for clinical use.
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Biomarkers and trial design issues
Pretreatment biomarkers

Prognostic biomarkers
Prognostic biomarkers are often part of a study's eligibili ty criteria; one example is a nomogram for estimating su rvival time. 27 Several nomograms incorporate baseline clinical parameters that are categorical (such as performance status, Gleason score, prior treatment, or sites of disease), and biological determinants that are continuous (such as PSA and lactate dehydrogenase [LDH] ). [27] [28] [29] In a nomogram, each parameter is assigned a separate score, and the sum of these scores is used to estimate the probability of an event in a certain number of years. Although the use of nomograms has improved our ability to estimate prognosis, when the di scriminatory accuracy of CRPC no mograms was examined, the known prognostic factors for overall survival and progression-free survival explained only a modest understanding of patient risk. 30, 31 This lack of predictive accuracy suggests that the practice of using nomogram-based prognoses to identify a 'similar' historical control group, rather than randomizing a contemporary control group, might lead to inaccurate clinical decisions.
Predictive biomarkers
Predictive biomarkers are typically considered to be bi ological or molecular determinants; for example, mutations that are associated with sensitivity to tyrosi ne kinase inhibitors. 32 They can also include clinical parameters, such as prior exposure to a specific therapy, response to therapy, or laboratory measurements such as serum te stosterone levels. 4 The PCWG2 def inition of castration-testosterone levels ≤50 ng/ml in the blood-was largely c onsensusbased, but also reflected the varied sensitivity of the te stosterone assays available. 16 In association with the recent approval of the CYP17 inhibitor abiraterone acetate, it was shown that much lower androgen levels (1-2 ng/ml) can be detected. 33 Now that mass spectroscopy-based assays that can measure androgens in this lower range are available, the definiti on of castration will change. As a result, and with the demonstrated survival benefit of the androgen receptor signalling inhibitor enzalutamide, 5 more studies are considering both prior hormonal exposure as well as measured te stosterone levels as part of the eligibility criteria for trials.
Common molecular alterations in CRPC include changes in the AR and the AR signalling axis, such as AR overexpression, increased androgen biosynthesis, splice variants and mutations, altered PTEN signalling, and translocations that allow the ETS tr anscription factor to be under the control of androgen. 34 Mutations in sp ecific receptor tyrosine kinases including EGFR or BRAF, common in other tumour types, are in frequent in p rostate cancer. [35] [36] [37] Reciprocal feedback inhibition between the AR and PTEN axes has also been described. 38 These and other molecular changes are being studied as both prognostic and predictive biomarkers. Unfortunately, none of the assays for these determinants in prostate cancer has been analytically validated yet, limiting our ability to explore the association of these changes with outcomes. The concordance correlation coefficient is computed to assess the reproducibility of the two assays. With the assays plotted against each other, the concordance correlation coefficient measures the variation of the points around a 45° line through the origin. The concordance correlation coefficient for the two assays equals 0.82. Indicates (estimates) the risk or likelihood that a patient who receives no further cancer-directed therapy will experience a specified clinical outcome, such as recurrence, progression, or death.
Predictive
Prior to treatment Interpreted with defined criteria to identify patients who are likely to benefit from a specific treatment compared to patients who do not meet the specified criteria.
Responseindicator During or after treatment
Demonstrates a pharmacological or physiological response to the treatment, but does not necessarily signify patient benefit. Examples are declines in prostate-specific antigen, measures of tumour shrinkage, or pharmacodynamic changes in a parameter to show the on-target effect of a drug as proof of mechanism or to optimize dosing.
Efficacyresponse (surrogate)
After treatment Provides an early and accurate prediction of both a clinical end point, and the effects of the treatment on that end point.
Post-treatment biomarkers Response-indicator biomarkers
A response-indicator biomarker shows that there has been a change following treatment, but does not necessarily indicate that a patient has benefitted from the treatment. Such biomarkers include pharmacodynamic measures to assess the on-target effects of a drug, a change in tumour size, and change in response criter ia. For instance, outcomes for most solid tumours are reported using RECIST. 39, 40 In most patients with metastatic prostate cancer, RECIST is not particularly useful because it does not adequately address PSA changes or the assessment of disease in bone. 39 It is for these reasons that PCWG2 recommended reporting the outcomes for each disease manifestation independently and specifically recommended against using the grouped categorizations of response in RECIST. 16 Response-indicator biomarkers in CRPC include the control and/or relief of symptoms; 41 post-therapy changes in PSA, which are now reported using waterfall plots; changes in bone scans (reported as improved; unchanged or stable; or progression); and changes in soft-tissue disease reported using RECIST 1.1, but re cognizing its limitations. Reporting outcomes individually for each disease manifestation enables a better understanding of the association between a specific parameter and clinical outcomes. 16 
Efficacy-response biomarkers
The control and relief of pain in patients with CRPC is a clinical benefit and has led to drug approvals. [41] [42] [43] Pain relief has been reported with docetaxel, 41 cabazitaxel, 2 abiratero ne, 44 radium-223 chloride, 12 and en zalutamide, 5 although none of these drugs has a formal pain relief in dication. Biomarkers to assess the presence of pain at baseline and change in pain post-treatment typically begin as individual measures on quality-of-life instrument ssuch as the Brief Pain Inventory 45 or QLC-30 46 -which then undergo a detailed validation process similar to the process performed for laboratory assays. Once validated, individual measures cannot be modified or taken out of context. 45, 47 Of the measures reported, maximal pain intensity in the previous 24 h has been used as an efficacy-response indicator of clinical benefit for drug approval. 45 More recently, dramatic improvements in bone scan assessment of lesion number, area, and intensit y, along with significant pain relief, were reported with cabozantinib. 48 Based on these findings, the COMET-2 trial was developed using a primary end point of pain palliation. 49 Docetaxel in combination with custirsen, an inhibitor of clusterin, is also undergoing study for the same indication. 50 
Prevent or delay biomarkers
Owing to the difficulties assessing response and the fr equent lack of association between a change in an in dividual disease parameter and clinical benefit, PCWG2 recommended focusing less on whether a treatment was working and more on when it had failed. 16 This shift has more-closely aligned the objectives of clinical research and clinical practice. To apply this approach requires a prospectivel y defined primary end point that can be measured with minimal bias and that is in itself a clinical benefit or can serve as a surrogate for that benefit. Prolonging life-defined as the delay or prevention of death from disease-is the gold standard for drug approval, as is a reduction or delay in the development of skeletal-related events. PSA progression, regardless of how it is defined, associates poorly with survival, 31 and no radiographic pr ogression biomarkers have been va lidated analytically.
To assess the adequacy of a biomarker-based t ime-to-progression end point, the association between the end point and survival time must be evaluated using a statistical measure that allows for censoring in both the time to death and the time to biomarker-derived progression; one example is the generalized version of Kendall rank correlation coefficient. 51 If a biomarker that closely associates with survival time is identified, its adequacy as a surrogate end point must be tested using multiple independent randomized clinical trials, the Prentice criteria being the most common conceptual framework for this. 52 In addition to randomized trials demonstratin g a treatment effect and the biomarker's association with survival, the Prentice criteria require that the treatment effect is fully explained by the newly constructed biomarker. However, this requirement is thought to be too high a standard to achieve: alternative continuous metrics have been proposed that measure the amount of the treatment effect explained by the biomarker. 23 The way forward-emerging biomarkers
Imaging biomarkers
Bone scintigraphy and PCWG2
To establish the performance characteristics of an imaging modality, each step of the process must be st andardized, including tracer manufacturing, tracer administration, the time to image acquisition, the methodology for acquiring the images, the definition and selection of data elements, and data collection. Qualitative and subjective descriptors are not sufficient. To ensure correlations can be performed consistentl y, researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) focus their initial studies on patients in a particular disease state, such as those with disease progression or who have metastatic disease visible on radionuclide bone scan. 53 Intuitively, it follows that prognosis varies inversely with disease extent; apart from considering the distribution of lesions (axial versus appendicular), 54 or groupings based on the number of lesions, 55 there remains no standard method of recording osseous disease, despite decades of bone scan use. 56 Therefore, PCWG2 first focused on post-treatment outcomes, and recommended that post-treatment effects on bone sc intigraphy be ch aracterized as improved, stable or worse (progression)-a highly subjective classification. At the same time, PCWG2 proposed a definition of progression as the appearance of two or more new lesions, with the recognition that a first follow-up scan might show new lesions that reflect bone healing and favourable effects of treatment, rather than treatment failure. To account for this flare phenomenon, and to ensure that an effective treatment was not dis continued prematurely, PCWG2 advised that the appearance of two or more new lesions on the first post-treatment scan should be confirmed with a follow-up scan showing two additional new lesions before the patient's disease can be considered as having progressed. After the follow-up (second) scan, the appearance of two new lesions on any scan is considered to show disease progression. 16 To test the PCWG2 criteria clinically, a bone scan in terpretation assay was developed to systematically collect and aggregate new lesions so that a definitive PCWG2-compliant date of progression could be de signated. The instrument was developed, tested, refined and validated at prostate cancer imaging research centres in the Prostate Cancer Clinical Trials Consortium over a period of years. It allows radiologists to record the seminal data points of bone imaging and record disease progressio n uniformly across study sites and across studies. 57 Following development of the bone-scan assay, the pr ogression measure was embedded into three phase III registration trials of active AR-targeted therapies powered to detect a survival advantage. 4 The first has been co mpleted, 4 and showed excellent concordance for interpretation between individual sites and central readers. 58 The results of the first trial were a supporting factor for the approval of abiraterone plus prednisone for chemotherapy pretreated patients, 59 and a revision of the in dication for the drugs to treat CRPC. The results from the other two studies are pending.
Bone scan index
Recognizing that the distribution of bone meta stases mirrors the distribution of the adult bone marrow, researchers at MSKCC developed the Bone Scan Index (BSI), a quantitative measure of tumour burden as a percentage of skeletal mass. The first clinical study of the BSI focused on reproducibility and showed an inter observer variability of less than 10%, and intraobserver c orrelation between a first and second reading of the same scan after a 2-year period of 0.97 and 0.94. 60 A study of 191 patients with progressive CRPC divided into equal tertiles showed inferior survival as BSI increased from <1.4%, 1.4-5.1%, and >5.1% (P = 0.0079). The prognostic significance of BSI was retained in a multivariate analysis that also included age, haemoglobin, and LDH. 60 Although simply counting new lesions is a reproducib le metric, it does not capture increases in the size of lesions. To address this, we studied serial changes in BSI over time as an outcome. In an initial series of 88 patients, pretreatment and post-treatment BSI was highly associated with survival, and in a multivariate model in which post-treatment changes in BSI were compared with post-treatment PSA changes, BSI was the most-significant marker co rrelated with outcome. A doubling of BSI conferred an almost twofold increase in the risk of death. 61 Further study in ongoing phase III trials is planned.
Automation of quantitative bone imaging
Conventional bone scans in patients with prostate cancer result in subjective interpretation, which is dependent on the skill of individual readers. For this reason, quantitative methods that are inherently more objective, such as BSI, have a definite appeal for assessing treatment effects. Recently, two computer-aided detection systems have been described: EXINI bone 62 (Exini Diagnostics, Lund, Sweden) and MedQIA 63 (MedQIA, Los Angeles, CA, USA). Both methods reproducibly segment and quantify lesions within a single scan and allow for the comparison of lesion measurements between consecutive scans. The EXINI system provides a BSI value that represents percentage of total skeletal mass involved by the tumour, whereas the MedQIA system assesses the lesion count, the area (Bone Scan Lesion Area [BSLA]), and intensity (Bone Scan Lesion Intensity [BSLI] ). The parameters of lesion count, BSLA, and BSLI were used to quantitatively demonstrate the significant post-treatment changes seen with cabozantinib, 48, 63 which have in turn resulted in the opening of a randomized placebo-controlled trial with overall survival as the primary end point (COMET-1). 64 It is likely that the introduction of these automated methods will make quantitative methods of bone scan evaluation more practical and readily standardized. 63 PET imaging Molecular imaging can assess both soft tissue and bone with a single modality, and inform on the biology of the tumour itself rather than its impact on the surrounding tissues. A variety of tracers are being explored that are at different stages of development. Each must follow the same process to justify regulatory approval.
Analytical validation
To use PET imaging as a biomarker, the tracer itself must undergo analytical validation that includes uniform tracer production and administration; image acquisition, data collection, and post-scanning data processing; defining its pharmacokinetic properties; establishing correlations with other imaging modalities and tissue; and data interpretation. 53 This validation is accomplished by maintaining the image biomarker as the primary variable in a prospectively defined cohort of patients.
Performance characteristics
The importance of controlling for confounding factors cannot be underestimated. For example, using a h eterogeneous population, it was originally po stulated that 18 F-fluorodeoxyglucose (FDG)-PET correlated poorly with known sites of disease. 65 By contrast, when imaging was restricted to patients with progressive disease, and the scans performed at fixed intervals, the outcomes were very different. In an analysis of 43 patients with metastatic CRPC, 1,720 bones were examined by bone sc intigraphy and compared with PET findings: 1,079 (63%) bones were negative on both modalities, and 400 (23%) were positive on both, a 90% concordance rate. 66, 67 Of the 121 mismatches where FDG-PET was positive and the bone scan was negative, 105 had follow-up bone scans and 84 (80%) were positive, suggesting that PET was superior in terms of detecti ng early metastatic disease.
Reproducibility can be further defined by performing two scans before any treatment is delivered. Such test and re-test studies are now underway in the Prostate Cancer Clinical Trials Consortium for sodium fluoride PET-CT, 68 a bone-imaging PET tracer likely to replace technetium bone scintigraphy. The 18 F-fluorodihydrotestosterone (FDHT)-PET tracer is being studied in a similar manner. 53 Such studies of reproducibility within a modality and between modalities must be performed with each imaging method studied (Figure 2 ).
Prognosis
PET imaging has the potential to serve as both a pr ognostic and response-indicator biomarker because it lends itself to quantification. Previous studies examined the hottest slice of the hottest lesion on the scan (SUV max ), the average of five index lesions (SUV maxavg ), or the uptake in a region around the maximal pixel (SUV peak ), and other measures. 69 In a multivariate analysis of a series of 96 patients with metastatic CRPC, only LDH and FDG-PET SUV maxavg were significantly associated with overall survival. 70 Response indicator Explorations of PET imaging as a response-indicator are ongoing. 69, 71 The PET measure that will be followed across the treatment interval is the biomarker-be it a single hottest slice, such as the SUV max , or the average of the hottest slices of a selected group of index lesions, such as the SUV maxavg . In one study of 22 patients with progressive CRPC undergoing treatment with anti microtubule chemotherapy who were scanned at b aseline, 4 weeks, and 12 weeks, SUV maxavg PET imaging, as a single measure, captured the post-treatment effects usually identified by an amalgam of PSA, bone imaging, and cross-sectional imaging. 71 These studies are labour intensive as they require manual measurements of individual lesions followed across time. Now, with an increase in automation and computing power, it is feasible to examine all of the lesions as opposed to a handful of index lesions. Figure 3 depicts a Larson-Fox-Gonen plot 72 that shows the individual lesions in a patient at baseline and after 1 month of treatment with a novel antiandrogen drug, e nzalutamide. Two tracers were administered, 18 FDHT to visualize the androgen receptor, and 18 FDG to vi sualize glucose metabolis m. The Larson-Fox-Gonen plot illustrates the heterogeneity of response in individual sites of meta stases using the two tracers, as well as the heterogeneit y of the lesions de monstrated by each single tracer.
Circulating tumour cells
Circulating tumour cells (CTCs) are estimated to re present less than one in a billion of the circulating mononuclear cells in the blood. 73 Methods to detect and isolate these cells typically include an enrichment step followed by a variety of techniques to enable en umeration, profilin g and/or biological characterization. 73, 74 Enrichment methods include those based on: physical characteristics such as density gradient centrifugation, filtration, dielectric focusing, or that exploit differences in cell plasticity; direct capture methods with a single antibody or antibody cocktail to cell-surface markers that are conjugated to magnetic ferrofluids, magnetic beads, microposts on chips, 75, 76 or for separation by flow cytometry techniques; indirect methods that deplete CD45-expressing mononuclear cells that leave the CTC population behind; a red-cell lysis followed by the direct deposit of the buffy coat on a microscope slide for future imaging; 77, 78 or the ability of cells to grow in vitro. 79 Detection and characterization can be achieved with tumour-specific or tissue-specific antibodies visualized with semi-automated microscopes, laser-sc anning techniques, or other DNA-based and RNA-based methods. 80, 81 No two assays measure the same CTC biomarker. Even two antibodies to different epitopes on the same protein might not give equivalent results in the clinic. As such, there is no single definition for a CTC or CTC biomarker to represent the full spectrum of tumour-derived cells in the circulation. These cells range from those with stem or stem-cell-like properties to those that have undergone an epithelial-mesenchym al transition (EMT) to fully di fferentiated cells. The se lection of an assay is dependent on the c linical context for which it will be used: no single assay can address all of the unmet needs that can be addressed with CTC biomarkers.
Analytical validation
The collection tubes for assays can differ: some have fi xatives to preserve the cells, while those for ribo nucleic acids, short-term culture, xenograft developmen t, or functional characterization generally do not. Some methods require sample processing within hours, and others provide consistent results up to several days after the blood draw. Sensitivity and specificity are issues for all of the techniques owing to the heterogeneity of tumour cells with respect to size, density, and marker expression. EpCAM is the most widely used capture antibody, and cyto keratins (CK8 or CK18) are the most widely used marker for the detection of CTCs from epithelial prostate tumours. 82 Either method might not capture or detect cells that have undergone EMT or that have stem cell or stem-cell-like properties, and va riations in expression levels 83 can lead to false-negatives.
Currently, CellSearch®(Veridex LLC, Warren, NJ, USA) is the only assay that is analytically valid and FDAapproved for patient use. 84 With this assay, CTCs are ca ptured using an EpCAM conjugated ferrofluid, and are defined after immunofluorescent staining as morphologically intact cells with a 4' ,6-diamidino-2-phenylindole (DAPI)-positive nucleus surrounded by cytoplasm that express the cytokeratins CK8, CK18 or CK19, but do not express CD-45. 85 The assay reports the number of cells in 7.5 ml of blood that meet the defined criteria; notably, this reported value represents a small proportion of the EpCAM-expressing cells captured (Figure 4) .
The assay was analytically validated using cellline-spikin g experiments, and with over 450 duplicate breast cancer patient samples showing consistent results over a wide range of cell numbers analysed in the same laboratory by different technicians, and in a reference laboratory compared to a local laboratory. 84 We showed that the cells captured expressed PSA and AMACR racemase, and that prostate cancer samples had unique copy number alterations and AR amplification by FISH. 85 
Prognosis
The prognostic significance of CTCs detected by CellSearch® was demonstrated in sequential studies of similar design (the IMMC38 series) that enrolled patients with breast, 86 colorectal 87 and prostate 88 cancer about to receive a new first-line or second-line chemotherapy regimen. In the prostate cancer study, CTC enumeration and PSA determinations were performed before treatment and at the start of a cycle; 89 assessment by imaging was discretionary. The prostate cancer results established a baseline value of four or fewer cells per 7.5 ml of blood as a favourable prognosis, whereas five or more cells per 7.5 ml of blood was associated with an unfavourable prognosis. 88 This finding was used to show the activity of hormonal agents, 90 and in sequential phase I trials of different targeted th erapies. 91 The cut-off point of five cells was based on differences in the hazard ratio (HR) for survival at different cut-off points at the lower end of the measurement scale. A similar association with survival was shown for CTC numbers analysed as a continuous variable. 89, 92 The wide range of survival times for patients with low CTC counts demonstrates that a low count alone does not assure a long survival. 92, 93 The predictive accuracy of CTC with survival analysed with the concordance probability estimate showed the discriminatory power of CTCs equal to 0.71, which increased to 0.74 with the addition of baseline LDH levels. 92 Response indicator A similar association between favourable versus un favourable CTC counts and survival was shown at different time points (2-5 weeks, 6-8 weeks, 9-12 weeks, and 16-20 weeks) post-treatment. 88 The association between the presence of CTCs with decreased overall survival led to the FDA clearance of the test "as an aid in the monitoring of [these] patients in conjunction with other clinical methods. " 84 A subsequent analysis of patients receiving their first cytotoxic therapy showed that CTC count was associated with overall survival as a continuous variable. In a multivariate analysis, only CTC count and LDH were prognostic, but PSA was no longer prognostic. 92 Similar results were observed in an analysis of men enrolled on a series of phase I and phase II trials of molecular-targeted agents. 94 Importantly, the FDA clearanc e does not establish CTC enumeration as an efficacy-response surrogate, and as such this biomarker cannot be used in regulatory submissions. However, it does establish the ability of the test result to inform pr ognosis pretreatment and post-treatment. 
Efficacy-response qualification
Qualifying CTC enumeration as an efficacy-response surrogate marker for survival requires consistent results in multiple phase III clinical trials where the biomarker is embedded. Based on the IMMC38 results, CTC en umeration (CellSearch®) was studied independently in two phase II abiraterone trials that enrolled men who had received prior chemotherapy for CRPC. It was notable that in this closely defined patient population the different trials (conducted at different sites) showed a similar frequency of unfavourable CTC counts at baseline and conversion rates post-treatment. 90, 95 The trial led by the Royal Marsden Hospital showed 79% of patients with unfavourable CTC counts at baseline and 41% converting to favourable CTC counts post-treatment. 90 The trial led by MSKCC showed 69% of patients with unfavourable CTC counts at baseline and 34% converting to favourable CTC counts post-treatment, 95 a consistency in outcome that strongly supports the reliability of the results. Based on these data, CTC enumeration was studied in the abiraterone phase III registration trial as an efficacy-response biomarker. 96 The final analysis of the phase III trial showed a median overall survival difference of 4.6 months in favour of abiraterone compared with placebo (15.8 months versus 11.2 months; HR = 0.74; P <0.0001). CTC conversion from unfavour able (CTC ≥5) to favourable (CTC <5) counts was predictiv e of overall survival as early as 4 weeks after beginning treatment, and its inclusion significantly explained the treatment effect at all post-treatment time points (HR = 0.74-0.97), a key component of the Prentice criteri a. 96 An analysis of whether the prognostic significance of CTC conversion is increased if it is combined with other biomarkers (such as LDH, haemoglobin, PSA levels) is planned. If it is, then the best combination of markers will be used as a CTC-based biomarker panel in subsequent trials. 97, 98 A goal of these studies is to determine whether this biomarker panel can be used as a s urrogate end point in future CRPC clinical trials.
Prediction and precision medicine
Optimal use of a targeted approach requires a demonstratio n that the target is present in an individual patient's tumour when therapy is considered. CTCs can originate from the primary tumour itself or from the metastatic sites, and potentially could be measured non-invasively, using a real-time liquid biopsy, for disease characterization to guide treatment selection. The specific CTC assay needed will depend on the determinant being studied. Presently, there are a wide range of assays, many of which are being used in patients without any analytica l or clinical validity. Caution must be exercised by both investigators and pr actitioners in the routine clinical use of these assays.
Conclusions
The development of biomarkers to inform drug developmen t requires a systematic and stepwise approach. It begins with an assessment of the performance characteristics and reproducibility of the measurement itself, fo llowed by a series of prospectively designed studies with adequate statistical support to demonstrate a clinical effect within a well-defined context. Analytical and clinical validation for a particular context of use are required steps for FDA approval (clinical qualification). At present, CTCs and imaging are promising candidates for informative new biomarkers. Together, they present the opportunity to examine a patient's entire disease burden, disease aggressiveness and disease biology. With each technology enhancement comes the burden of starting the biomarker validation and qualification process from the beginning. This requirement includes the analytical validation of devices, assays, and software, as well as the data elements and outputs. The statistical and computational methodologies to describe this wealth of data are also rapidly evolving. There are no shortcuts, but through focused efforts significant advances have been realized and promise to continue. 
Review criteria
A formal literature search was performed using the PubMed database and the following terms: "prostate cancer biomarkers", "clinical trials", "trial design", "response" and "endpoints". The authors used their own judgment about which papers to include from the literature search based on the relevance of the article to the clinical scenario. This Review also includes a summary of the authors' work and knowledge based on reading the oncology literature. Knowledge gained from regular attendance at conferences, workshops, and other national and international meetings was also included.
